Prostate cancer epidemiology in the United States

World Journal of Urology

Volumn 30, Issue 2, 2012, Pages 195-200

  Brawley, Otis W ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Epidemiology; Incidence; Mortality; Population studies; Prostate cancer; Race; Survival rates

Indexed keywords

AGE DISTRIBUTION; AGED; HUMAN; INCIDENCE; MALE; MIDDLE AGED; PROSTATE TUMOR; RACE; REVIEW; RISK FACTOR; SURVIVAL RATE; UNITED STATES;

AGE DISTRIBUTION; AGED; CONTINENTAL POPULATION GROUPS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 84859439993     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-012-0824-2     Document Type: Review

References (37)

1. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.
2. Altekruse SF, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalocich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK (2010) SEER cancer statistics review, 1975-2007. National Cancer Institute, Bethesda.
3. Merrill RM, Feuer EJ, Warren JL et al (1999) Role of transurethral resection of the prostate in population-based prostate cancer incidence rates. Am J Epidemiol 150: 848-860.
4. Potosky AL, Miller BA, Albertsen PC, Kramer BS (1995) The role of increasing detection in the rising incidence of prostate cancer. JAMA 273: 548-552.
5. Catalona WJ, Smith DS, Ratliff TL et al (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324: 1156-1161.
6. Crawford ED, DeAntoni EP, Etzioni R et al (1996) Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The prostate cancer education council. Urology 47: 863-869.
7. Boyle P (2003) Screening for prostate cancer: have you had your cholesterol measured? BJU Int 92: 191-199.
8. Brawley OW, Jani AB (2007) Race and disparities in health. Curr Probl Cancer 31: 114-122.
9. Lu-Yao G, Albertsen PC, Stanford JL et al (2008) Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up. J Gen Intern Med 23: 1809-1814.
10. Lu-Yao GL, Potosky AL, Albertsen PC et al (1996) Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst 88: 166-173.
11. Wright JL, Salinas CA, Lin DW et al (2009) Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort. J Urol 182: 2702-2707.
12. Jani AB, Master VA, Rossi PJ et al (2007) Grade migration in prostate cancer: an analysis using the surveillance, epidemiology, and end results registry. Prostate Cancer Prostatic Dis 10: 347-351.
13. Draisma G, Boer R, Otto SJ et al (2003) Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer. J Natl Cancer Inst 95: 868-878.
14. Etzioni R, Penson DF, Legler JM et al (2002) Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J Natl Cancer Inst 94: 981-990.
15. Welch HG, Albertsen PC (2009) Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 101: 1325-1329.
16. Magheli A, Rais-Bahrami S, Humphreys EB et al (2007) Impact of patient age on biochemical recurrence rates following radical prostatectomy. J. Urol 178: 1933-1937; discussion 1937-1938.
17. Hemminki K (2012) Family risk and familial survival in prostate cancer. WJUR X: XXX-XXX.
18. Brandt A, Bermejo JL, Sundquist J, Hemminki K (2010) Age-specific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family members. Eur Urol 58: 275-280.
19. Marshall JR (2012) Diet and prostate cancer prevention. WJUR X: XXX-XXX.
20. Hayes RB, Ziegler RG, Gridley G et al (1999) Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev 8: 25-34.
21. Giovannucci E (2011) Commentary: serum lycopene and prostate cancer progression: a re-consideration of findings from the prostate cancer prevention trial. Cancer Causes Control 22: 1055-1059.
22. Giovannucci E (2005) Tomato products, lycopene, and prostate cancer: a review of the epidemiological literature. J Nutr 135: 2030S-2031S.
23. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 348: 1625-1638.
24. McGreevy KM, Hoel BD, Lipsitz SR, Hoel DG (2007) Impact of nutrients on insulin-like growth factor-I, insulin-like growth factor binding protein-3 and their ratio in African American and white males. Public Health Nutr 10: 97-105.
25. Rebbeck T (2012) Using a global approach to inform prostate cancer prevention and control. WJUR X: XXX-xxx.
26. Major JM, Cross AJ, Watters JL et al (2011) Patterns of meat intake and risk of prostate cancer among African-Americans in a large prospective study. Cancer Causes Control 22: 1691-1698.
27. Amling CL, Kane CJ, Riffenburgh RH et al (2001) Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology 58: 723-728.
28. Lange EM, Sarma AV, Ray A et al (2008) The androgen receptor CAG and GGN repeat polymorphisms and prostate cancer susceptibility in African-American men: results from the Flint Men's Health Study. J Hum Genet 53: 220-226.
29. Tseng M, Giri V, Watkins-Bruner D, Giovannucci E (2009) Dairy intake and 1, 25-dihydroxyvitamin D levels in men at high risk for prostate cancer. Cancer Causes Control 20: 1947-1954.
30. Bennett CL, Ferreira MR, Davis TC et al (1998) Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer. J Clin Oncol 16: 3101-3104.
31. Fedewa SA, Etzioni R, Flanders WD et al (2010) Association of insurance and race/ethnicity with disease severity among men diagnosed with prostate cancer, National Cancer Database 2004-2006. Cancer Epidemiol Biomarkers Prev 19: 2437-2444.
32. Whittemore AS, Kolonel LN, Wu AH et al (1995) Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 87: 652-661.
33. Hoffman RM, Harlan LC, Klabunde CN et al (2003) Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study. J Gen Intern Med 18: 845-853.
34. Klabunde CN, Potosky AL, Harlan LC, Kramer BS (1998) Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care 36: 1337-1348.
35. Shavers VL, Brown M, Klabunde CN et al (2004) Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer. Med Care 42: 239-250.
36. Shavers VL, Brown ML, Potosky AL et al (2004) Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med 19: 146-155.
37. Optenberg SA, Thompson IM, Friedrichs P et al (1995) Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. JAMA 274: 1599-1605.